Biotron
ASX:BTRNSydney, Australia· Est.
Australian‑stage antivirals targeting viroporins to treat HIV, HCV and emerging viral diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Australian‑stage antivirals targeting viroporins to treat HIV, HCV and emerging viral diseases.
Infectious Diseases
Technology Platform
Proprietary bacterial cell‑based screening platform to discover small‑molecule inhibitors of viral viroporin ion channels.
Opportunities
Successful Phase 2 data for BIT225 could unlock large HIV‑1 and HCV markets and attract partnership or licensing deals, while the viroporin platform offers a pipeline of antivirals against emerging infectious threats.
Risk Factors
Clinical trial failure, limited cash runway without additional financing, and competition from established antiviral developers could impede progress.
Competitive Landscape
Biotron’s viroporin‑targeting strategy is distinct from conventional protease or polymerase inhibitors, providing a novel mechanism that may offer synergistic combination potential against competitors.